ARCUTIS BIOTHERAPEUTICS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $13.25 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-08-05
- ARCUTIS BIOTHERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2026-03-31 was $9.16, a 130.73% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2025-03-31 was $3.97, a 82.85% decline year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2024-03-31 was $23.15, a 4.51% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2023-03-31 was $22.15, a 24.81% decline year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2025 was $9.55, a 57.31% decline from fiscal 2024.
- ARCUTIS BIOTHERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2024 was $22.37, a 9.44% increase from fiscal 2023.
- ARCUTIS BIOTHERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was $20.44, a 16.94% decline from fiscal 2022.
- ARCUTIS BIOTHERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2022 was $24.61, a 11.31% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $13.25 10-Q · filed 2026-08-05 | |||
| 2026-03-31 | $9.16 10-Q · filed 2026-05-06 | |||
| 2025-12-31 | $9.55 10-K · filed 2026-02-25 | |||
| 2025-09-30 | $9.55 10-Q · filed 2025-10-28 | |||
| 2025-06-30 | $9.61 10-Q · filed 2025-08-06 | |||
| 2025-03-31 | $3.97 10-Q · filed 2025-05-06 | |||
| 2024-12-31 | $22.37 10-K · filed 2025-02-25 | |||
| 2024-09-30 | $22.49 10-Q · filed 2024-11-06 | |||
| 2024-06-30 | $23.05 10-Q · filed 2024-08-14 | |||
| 2024-03-31 | $23.15 10-Q · filed 2024-05-14 | |||
| 2023-12-31 | $20.44 10-K · filed 2024-02-27 | |||
| 2023-09-30 | $20.48 10-Q · filed 2023-11-03 | |||
| 2023-06-30 | $20.25 10-Q · filed 2023-08-08 | |||
| 2023-03-31 | $22.15 10-Q · filed 2023-05-09 | |||
| 2022-12-31 | $24.61 10-K · filed 2023-02-28 | |||
| 2022-09-30 | $25.52 10-Q · filed 2022-11-08 | |||
| 2022-06-30 | $25.40 10-Q · filed 2022-08-04 | |||
| 2022-03-31 | $29.46 10-Q · filed 2022-05-05 | |||
| 2021-12-31 | $22.11 10-K · filed 2022-02-22 | |||
| 2021-09-30 | $22.32 10-Q · filed 2021-11-04 | |||
| 2021-06-30 | $20.27 10-Q · filed 2021-08-05 | |||
| 2021-03-31 | $28.65 10-Q · filed 2021-05-06 | |||
| 2020-12-31 | $22.82 10-K · filed 2021-02-16 | |||
| 2020-09-30 | $27.61 10-Q · filed 2020-11-05 | |||
| 2019-12-31 | $0.58 10-K · filed 2021-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |